Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Renal Cell Carcinoma

Therapeutic area intelligence for Renal Cell Carcinoma with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
8
Catalysts
0
Companies
2

Companies

Merck →
Tarix Pharmaceuticals →

Assets

Axitinib →
cabozantinib →
Histotripsy →
KEYTRUDA →
LNK001 →
pembrolizumab →
sunitinib →

Recent signals(8)

ClinicalJuly 26, 2026

Histotripsy Shows Promise for Noninvasive Treatment of Renal Cell Carcinoma

Histotripsy is a non-invasive ablation technique showing potential for treating renal cell carcinoma, with promising results from animal studies.

ClinicalJuly 19, 2026

Study on 124I-cG250 PET/CT for Early Detection of Therapy Response in Metastatic Renal Cell Carcinoma

A study is evaluating the effectiveness of 124I-cG250 PET/CT scans in detecting early responses to sunitinib or pazopanib in kidney cancer patients.

ClinicalJuly 16, 2026

Phase 1 Study of LNK001 in Advanced Clear Cell Renal Cell Carcinoma Initiated

A Phase 1 study of LNK001 is underway to determine the recommended dose and efficacy in advanced ccRCC.

ClinicalJune 30, 2026

Cabozantinib plus Nivolumab Shows Promise in Advanced Non-Clear Cell RCC

In a study of 62 patients with advanced non-clear cell renal cell carcinoma, cabozantinib plus nivolumab achieved an objective response rate of 45.2% and a disease control rate of 93.6%.

ClinicalJune 26, 2026

Axitinib and Survivin Vaccine Enhance PD-1 Therapy in Renal Carcinoma

Sequential treatment with axitinib followed by a survivin vaccine and PD-1 blockade leads to durable tumor control in renal carcinoma.

RegulatoryJune 22, 2026

FDA approves belzutifan with pembrolizumab for renal cell carcinoma treatment

The FDA has approved belzutifan in combination with pembrolizumab for the adjuvant treatment of renal cell carcinoma.

ClinicalJune 17, 2026

Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC

The Phase 3 LITESPARK-012 trial did not meet its dual primary endpoints of progression-free survival and overall survival for the evaluated combination therapies.

RegulatoryJune 13, 2026

FDA Approves KEYTRUDA Combinations for Adjuvant Treatment in Clear Cell RCC

The FDA has approved KEYTRUDA and KEYTRUDA QLEX in combination with WELIREG for adjuvant treatment in ccRCC patients, marking a significant advancement in therapy.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Renal Cell Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.